The latest results from the GfK Disease Atlas, an international program that brings together evidence from various clinical cases for physicians and patients, have revealed major shortcomings in the treatment of patients suffering from atopic dermatitis.

An international survey of clinicians and patients found that 43% of dermatologists treating moderate to severe AD in adults with potent topical steroids were dissatisfied with the level of control achieved. The same dissatisfaction is experienced by 66% of patients.

Worse, for patients, this dissatisfaction is quite expected: 92% say that the doctor explained to them what the results of the treatment will be. And 91% percent of them are ready to undergo repeated treatment if prescribed by their doctor.

More than 4 out of 10 doctors and 6 out of 10 patients are dissatisfied with the level of control that is being exercised on adults with moderate to severe atopic dermatitis who have been treated with potent topical steroids.

91% of adults with moderate to severe atopic dermatitis who have been treated with potent topical steroids will need to be retreated.

Background: The GfK Disease Atlas Atopic Dermatitis Program covers eight countries, providing data processing for more than 4,000 adults and children with atopic dermatitis by more than 800 clinicians. Similar programs have also been created for acne, psoriasis and rheumatology.

The same disadvantages are noted in another typical treatment for moderate to severe atopic dermatitis - the use of oral steroids. The level of dissatisfaction of doctors and patients with the results of treatment is almost the same.

"The lack of new treatments for atopic dermatitis means that patients often repeat the same courses of treatment - with steroids," says Alison Rose, head of dermatology and immunology at GfK. “But the low level of satisfaction we see among physicians and patients with these routine procedures indicates huge potential for any players entering this market with new therapeutic options.”

GfK will bring a more comprehensive view of modern dermatology at the World Congress of Dermatology, which will be held in Vancouver, Canada from June 8-13.

Add a comment

captcha

RefreshRefresh